Skip to content
value.today

N30 Pharmaceuticals, Inc.

Formerly N30 Pharmaceuticals, LLC

Total raised
$206 M
4 rounds on record
Latest round
$91 M
Sep 2021
First round on record
Nov 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of N30 Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2021$91 MNo. 4$50 to $250 million

N30 Pharmaceuticals, Inc.: Raise no. 4, Sep 2021

Investors in this round

16 investors had bought by the notice of Sep 29, 2021: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for N30 Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$91 M of $91 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Paul Rickey · Executive Officer · Senior Vice President and Chief Financial Officer
  • Mitchell Paul Gold · Executive Officer, Director · Executive Chairman and Chief Executive Officer
  • Stanford Paul Peng · Executive Officer · President and Head of Research and Development
  • Zelanna Paul Goldberg · Executive Officer
  • Christopher Paul Peetz · Director
  • Cui Paul Xiangmin · Director
  • James Paul Topper · Director
  • Jay Paul Venkatesan · Director
  • Natasha Paul Hernday · Director
  • Peter Paul Thompson · Director
  • Robert Paul Conway · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Issuer issued and sold 6,489,357 shares and 3,191,487 prefunded warrants to purchase shares at an exercise price of $0.001 per share. The purchase price of the shares and the prefunded warrants was $9.40 per security.”

Signed by James Paul Rickey, Senior VP and CFO. Source: SEC Form D, newest notice filed Sep 29, 2021. Read the notice at the SEC.

equity, optionsSEC
Jul 2020$60 MNo. 3$50 to $250 million

N30 Pharmaceuticals, Inc.: Raise no. 3, Jul 2020

Investors in this round

25 investors had bought by the notice of Aug 7, 2020: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for N30 Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $83 M offered; $23 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,340,002
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Paul Rickey · Executive Officer · Senior Vice President and Chief Financial Officer
  • Mitchell Paul Gold · Executive Officer, Director · Executive Chairman and Chief Executive Officer
  • Stanford Paul Peng · Executive Officer · President and Head of Research and Development
  • Christopher Paul Peetz · Director
  • Cui Paul Xiangmin · Director
  • James Paul Topper · Director
  • Jay Paul Venkatesan · Director
  • Paul Paul Sekhri · Director
  • Peter Paul Thompson · Director
  • Robert Paul Conway · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Oppenheimer & Co. Inc. (CRD 249) · New York, New YorkSold in CA, IL, MA, NY, PA, TX, and outside the US
  • Cowen and Company (CRD 7616) · New York, New YorkSold in CA, IL, MA, NY, PA, TX, and outside the US

Remarks in the notice

  • On the amounts: “5,930,320 units were sold at a price per unit of $10.1175. Each unit consisted of a share of common stock, or a prefunded warrant to purchase one share, and a warrant to purchase 0.3 shares of common stock at exercise price per share of $12.74.”

Signed by James Paul Rickey, Senior VP and CFO. Source: SEC Form D, newest notice filed Aug 7, 2020. Read the notice at the SEC.

equity, optionsSEC
Jan 2019$25 MNo. 2$10 to $50 million

N30 Pharmaceuticals, Inc.: Raise no. 2, Jan 2019

Investors in this round

8 investors had bought by the notice of Jan 30, 2019: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for N30 Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $49 M offered; $23 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$907,499
Finders' fees
$75,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Paul Rickey · Executive Officer · Senior Vice President and Chief Financial Officer
  • Mark James Litton · Executive Officer · President and Chief Operating Officer
  • Mitchell James Gold · Executive Officer, Director · Executive Chairman and Chief Executive Officer
  • Stanford James Peng · Executive Officer · Executive Vice President of Research and Development and Chief Medical Officer
  • Christopher James Peetz · Director
  • Cui James Xiangmin · Director
  • James James Topper · Director
  • Jay James Venkatesan · Director
  • Paul James Sekhri · Director
  • Peter James Thompson · Director
  • Robert James Conway · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Piper Jaffray & Co. (CRD 665) · Minneapolis, MinnesotaSold in CA, IL, MA, MD, NY, OR, UT, VT, WA, and outside the US

Remarks in the notice

  • On the amounts: “The Issuer sold an aggregate of 4,706,700 units to the investors at a price per unit of $5.37. Each unit consisted of one share of common stock and a warrant to purchase 0.39 of a share of common stock at an exercise price per share of $12.74.”

Signed by James Paul Rickey, Senior VP and CFO. Source: SEC Form D, newest notice filed Jan 30, 2019. Read the notice at the SEC.

equity, optionsSEC
Nov 2014$30 MNo. 1$10 to $50 million

N30 Pharmaceuticals, Inc.: Raise no. 1, Nov 2014

Investors in this round

12 investors had bought by the notice of Nov 25, 2014: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for N30 Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $40 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$845,624
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Tom Sokolowski · Executive Officer
  • Evan Loh · Director
  • Howard Furst · Director
  • John Moore · Director
  • Jonathan Leff · Director
  • Joseph Loscalzo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Plus the issuance of 288,596 shares of Preferred Stock”

Signed by Tom Sokolowski, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 25, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • N30 Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2021).

    SEC Form D · Sep 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2021

That is all the official record says: N30 Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in N30 Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design Fund II, L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design Fund L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design International II, Ltd.Companynot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design International, L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Estate of Arnold H. Snider, IIIPersonnot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Hadley Harbor Master Investors (Cayman) L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Hawkes Bay Master Investors (Cayman) L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Jennison Global Healthcare Master Fund, Ltd.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Rock Springs Capital Management LPFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 25 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by N30 Pharmaceuticals, Inc.
NameRoleNamed in
James Paul RickeySenior Vice President and Chief Financial OfficerSep 2021
Mitchell Paul GoldExecutive Chairman and Chief Executive OfficerSep 2021
Stanford Paul PengPresident and Head of Research and DevelopmentSep 2021
Zelanna Paul GoldbergExecutive officerSep 2021
Mark James LittonPresident and Chief Operating OfficerJan 2019
Mitchell James GoldExecutive Chairman and Chief Executive OfficerJan 2019
Stanford James PengExecutive Vice President of Research and Development and Chief Medical OfficerJan 2019
Tom SokolowskiExecutive officerNov 2014
Christopher Paul PeetzDirectorSep 2021
Cui Paul XiangminDirectorSep 2021
James Paul TopperDirectorSep 2021
Jay Paul VenkatesanDirectorSep 2021
Mitchell Paul GoldExecutive Chairman and Chief Executive OfficerSep 2021
Natasha Paul HerndayDirectorSep 2021
Peter Paul ThompsonDirectorSep 2021
Robert Paul ConwayDirectorSep 2021
Paul Paul SekhriDirectorAug 2020
Christopher James PeetzDirectorJan 2019
Cui James XiangminDirectorJan 2019
James James TopperDirectorJan 2019
Jay James VenkatesanDirectorJan 2019
Mitchell James GoldExecutive Chairman and Chief Executive OfficerJan 2019
Paul James SekhriDirectorJan 2019
Peter James ThompsonDirectorJan 2019
Robert James ConwayDirectorJan 2019
Evan LohDirectorNov 2014
Howard FurstDirectorNov 2014
John MooreDirectorNov 2014
Jonathan LeffDirectorNov 2014
Joseph LoscalzoDirectorNov 2014